Skip to main content
Erschienen in: CNS Drugs 8/2011

01.08.2011 | Adis Drug Evaluation

Rotigotine Transdermal Patch

A Review of its Use in the Treatment of Parkinson’s Disease

verfasst von: Mark Sanford, Lesley J. Scott

Erschienen in: CNS Drugs | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro®) is indicated as monotherapy for the treatment of early Parkinson’s disease and as combination therapy with levodopa throughout the course of the disease.
Daily application of the rotigotine transdermal patch (referred to here as rotigotine) provided predictable release and absorption of rotigotine, with steadystate rotigotine concentrations reached within 1–2 days. In six large, well designed clinical trials, rotigotine was an efficacious treatment for Parkinson’s disease. In early Parkinson’s disease, rotigotine initiated without levodopa produced significantly greater improvements than placebo in the Unified Parkinson’s Disease Rating Scale (UPDRS) summed motor and activities of daily living (ADL) scores, as well as significantly higher response rates. In a comparison with oral ropinirole, rotigotine did not meet a prespecified response-rate noninferiority criterion, although this may reflect the dosages used, which may not have been directly comparable. In advanced Parkinson’s disease, rotigotine in combination with levodopa reduced ‘off’ time and improved motor functioning and ADL significantly more than levodopa plus placebo. Rotigotine was noninferior to oral pramipexole in reducing ‘off’ time, although it did not meet a response-rate noninferiority criterion. A recent trial focused on both motor and non-motor endpoints in patients with inadequate early morning motor control despite anti-parkinsonian treatment (most received levodopa). Rotigotine improved morning motor functioning and reduced sleep disturbances, night-time motor symptoms, depressive symptoms, pain and functioning, and quality of life to a significantly greater extent than placebo. Rotigotine was generally well tolerated across the trials and in longer-term extension studies, with the most common treatment-emergent adverse events being application-site reactions, gastrointestinal disturbances, somnolence and headache. Application-site reactions were generally mild to moderate in severity; where reported, up to 3% of patients had severe skin reactions.
Thus, rotigotine offers a novel approach to the treatment of Parkinson’s disease and, given its ease of administration, efficacy in reducing disabling motor and non-motor symptoms, and acceptable tolerability profile, it has the potential to be an attractive treatment option for this highly debilitating disease.
Literatur
1.
Zurück zum Zitat LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med 2008; 359(23): 2468–76PubMedCrossRef LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med 2008; 359(23): 2468–76PubMedCrossRef
3.
Zurück zum Zitat Poewe W, Mahlknecht P. The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 2009 Dec; 15 Suppl. 4:S28–32PubMedCrossRef Poewe W, Mahlknecht P. The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 2009 Dec; 15 Suppl. 4:S28–32PubMedCrossRef
4.
5.
Zurück zum Zitat Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009 May 26; 72 Suppl. 4: S1–136PubMedCrossRef Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009 May 26; 72 Suppl. 4: S1–136PubMedCrossRef
6.
Zurück zum Zitat Chen JJ, Swope DM, Dashtipour K, et al. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy 2009 Dec; 29(12): 1452–67PubMedCrossRef Chen JJ, Swope DM, Dashtipour K, et al. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy 2009 Dec; 29(12): 1452–67PubMedCrossRef
7.
Zurück zum Zitat Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25(7): 858–66PubMedCrossRef Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25(7): 858–66PubMedCrossRef
8.
Zurück zum Zitat Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson’s disease revisited: clinical features, natural history, and mortality. Mov Disord 1998 Nov; 13(6): 885–94PubMedCrossRef Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson’s disease revisited: clinical features, natural history, and mortality. Mov Disord 1998 Nov; 13(6): 885–94PubMedCrossRef
9.
Zurück zum Zitat Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson’s disease. CNS Drugs 2007; 21(12): 1039–55PubMedCrossRef Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson’s disease. CNS Drugs 2007; 21(12): 1039–55PubMedCrossRef
11.
Zurück zum Zitat Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn-Schmiedebergs Arch Pharmacol 2009; 379(1): 73–86PubMedCrossRef Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn-Schmiedebergs Arch Pharmacol 2009; 379(1): 73–86PubMedCrossRef
12.
Zurück zum Zitat Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007 Jan; 356(1): 39–46PubMedCrossRef Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007 Jan; 356(1): 39–46PubMedCrossRef
13.
Zurück zum Zitat Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 1994 Mar; 9(2): 147–54PubMedCrossRef Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 1994 Mar; 9(2): 147–54PubMedCrossRef
14.
Zurück zum Zitat Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson’s disease. Exp Neurol 2007 Feb; 203(2): 415–22PubMedCrossRef Scheller D, Chan P, Li Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson’s disease. Exp Neurol 2007 Feb; 203(2): 415–22PubMedCrossRef
15.
Zurück zum Zitat Scheller D, Dürmüller N, Peyon G, et al. Continuous administration of rotigotine enhances wakefulness but may deepen sleep in 6-OHDA lesioned rats [abstract no. P10.11]. 2nd World Parkinson Congress; 2010 Sep 28–Oct 1; Glasgow Scheller D, Dürmüller N, Peyon G, et al. Continuous administration of rotigotine enhances wakefulness but may deepen sleep in 6-OHDA lesioned rats [abstract no. P10.11]. 2nd World Parkinson Congress; 2010 Sep 28–Oct 1; Glasgow
16.
Zurück zum Zitat Scheller D, Stichel-Gunkel C, Lübbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease. Neurosci Lett 2008 Feb 13; 432(1): 30–4PubMedCrossRef Scheller D, Stichel-Gunkel C, Lübbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease. Neurosci Lett 2008 Feb 13; 432(1): 30–4PubMedCrossRef
17.
Zurück zum Zitat Harder S, Hesse M, Scheller D, et al. Rotigotine protects dopaminergic neurons under stress conditions via P13-Akt signalling and stimulation of phase II oxidants [abstract no. SC234]. Eur J Neurology 2010; 17 Suppl. 3: 53 Harder S, Hesse M, Scheller D, et al. Rotigotine protects dopaminergic neurons under stress conditions via P13-Akt signalling and stimulation of phase II oxidants [abstract no. SC234]. Eur J Neurology 2010; 17 Suppl. 3: 53
18.
Zurück zum Zitat Borta A, Arias-Carrión O, Nordmeyer M, et al. The dopamine agonist rotigotine stimulates precursor cell proliferation in adult rat brains [abstract no. P2541]. Eur J Neurol 2009; 16 Suppl. 3: 516 Borta A, Arias-Carrión O, Nordmeyer M, et al. The dopamine agonist rotigotine stimulates precursor cell proliferation in adult rat brains [abstract no. P2541]. Eur J Neurol 2009; 16 Suppl. 3: 516
19.
Zurück zum Zitat Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37(10): 2055–60PubMedCrossRef Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37(10): 2055–60PubMedCrossRef
20.
Zurück zum Zitat Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease [abstract no. P1245]. Eur J Neurol 2005; 12 Suppl. 2: 96 Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease [abstract no. P1245]. Eur J Neurol 2005; 12 Suppl. 2: 96
21.
Zurück zum Zitat The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8CrossRef The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8CrossRef
22.
Zurück zum Zitat Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 Jan 23; 68(4): 272–6PubMedCrossRef Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007 Jan 23; 68(4): 272–6PubMedCrossRef
23.
Zurück zum Zitat Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized,double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22(16): 2398–404PubMedCrossRef Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized,double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22(16): 2398–404PubMedCrossRef
24.
Zurück zum Zitat LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. The SP650 Study Group. Neurology 2007 Apr 17; 68(16): 1262–7 LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. The SP650 Study Group. Neurology 2007 Apr 17; 68(16): 1262–7
25.
Zurück zum Zitat Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 Jun; 6(6): 513–20PubMedCrossRef Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 Jun; 6(6): 513–20PubMedCrossRef
26.
Zurück zum Zitat Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011 Jan; 26(1): 90–9PubMedCrossRef Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011 Jan; 26(1): 90–9PubMedCrossRef
28.
Zurück zum Zitat Fleming TR. Addressing missing data in clinical trials. Ann Intern Med 2011 Jan 18; 154(2): 113–7PubMed Fleming TR. Addressing missing data in clinical trials. Ann Intern Med 2011 Jan 18; 154(2): 113–7PubMed
29.
Zurück zum Zitat Watts R, Pahwa R, Lyons K, et al. Long-term safety of rotigotine transdermal patch in early-stage Parkinson’s disease: four year results [abstract no. P2.174]. Parkinsonism Relat Disord 2009; 15 Suppl. 2: S137 Watts R, Pahwa R, Lyons K, et al. Long-term safety of rotigotine transdermal patch in early-stage Parkinson’s disease: four year results [abstract no. P2.174]. Parkinsonism Relat Disord 2009; 15 Suppl. 2: S137
30.
Zurück zum Zitat Watts RL, Boroojerdi B, Wallen LM. Long-term safety and efficacy of the rotigotine transdermal patch in early-stage Parkinson’s disease [abstract no. P05.136]. Neurology 2006; 66(5 Suppl. 2): A293 Watts RL, Boroojerdi B, Wallen LM. Long-term safety and efficacy of the rotigotine transdermal patch in early-stage Parkinson’s disease [abstract no. P05.136]. Neurology 2006; 66(5 Suppl. 2): A293
31.
Zurück zum Zitat Watts RL, Boroojerdi B, Jankovic J. Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson’s disease [abstract no. 386 plus poster]. 14th International Congress of Parkinson’s disease and Movement Disorders; 2010 Jun 13–17; Buenos Aires Watts RL, Boroojerdi B, Jankovic J. Open-label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson’s disease [abstract no. 386 plus poster]. 14th International Congress of Parkinson’s disease and Movement Disorders; 2010 Jun 13–17; Buenos Aires
32.
Zurück zum Zitat Giladi N, Surmann E, Boroojerdi B. The safety and efficacy of transdermal rotigotine over a 6-year period in patients with early-stage idiopathic Parkinson’s disease: SP716 Study Group. Mov Disord 2011; 26 Suppl. 2: 128–9 Giladi N, Surmann E, Boroojerdi B. The safety and efficacy of transdermal rotigotine over a 6-year period in patients with early-stage idiopathic Parkinson’s disease: SP716 Study Group. Mov Disord 2011; 26 Suppl. 2: 128–9
33.
Zurück zum Zitat LeWitt PA, Boroojerdi B, Poewe W, et al. Long-term treatment of advanced Parkinsons disease with rotigotine [abstract]. Neurology 2010; 74(9 Suppl. 2): A350 LeWitt PA, Boroojerdi B, Poewe W, et al. Long-term treatment of advanced Parkinsons disease with rotigotine [abstract]. Neurology 2010; 74(9 Suppl. 2): A350
34.
Zurück zum Zitat Trenkwalder C, Kies B, Dioszeghy P, et al. The effects of rotigotine on motor function and sleep over a 1-year period in patients with idiopathic Parkinson’s disease: results from an open-label extension study of RECOVER. SP915 Study Group [abstract]. Mov Disord 2011; 26 Suppl. 2: S14 Trenkwalder C, Kies B, Dioszeghy P, et al. The effects of rotigotine on motor function and sleep over a 1-year period in patients with idiopathic Parkinson’s disease: results from an open-label extension study of RECOVER. SP915 Study Group [abstract]. Mov Disord 2011; 26 Suppl. 2: S14
35.
Zurück zum Zitat Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 May; 64(5): 676–82PubMedCrossRef Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007 May; 64(5): 676–82PubMedCrossRef
36.
Zurück zum Zitat Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the Unified Parkinson’s Disease Rating Scale. Arch Neurol 2010 Jan; 67(1): 64–70PubMedCrossRef Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the Unified Parkinson’s Disease Rating Scale. Arch Neurol 2010 Jan; 67(1): 64–70PubMedCrossRef
37.
Zurück zum Zitat Trenkwalder C, Kies B, Rudzinska M, et al. Effect of rotigotine on sleep and nocturnal symptoms in Parkinson’s disease: RECOVER study [abstract no. 759 plus poster]. 14th International Congress of Parkinson’s Disease and Movement Disorders 2010 Jun 13–17; Buenos Aires Trenkwalder C, Kies B, Rudzinska M, et al. Effect of rotigotine on sleep and nocturnal symptoms in Parkinson’s disease: RECOVER study [abstract no. 759 plus poster]. 14th International Congress of Parkinson’s Disease and Movement Disorders 2010 Jun 13–17; Buenos Aires
38.
Zurück zum Zitat Chaudhuri KR, Friedman JH, Surmann E, et al. The effects of transdermal rotigotine on mood/cognition: interpretations from a post-hoc analysis of the RECOVER study using the Parkinson’s Disease Non-Motor Symptom Scale [abstract no. 367]. RECOVER Study Group. Mov Disord 2011 May; 26 Suppl. 2: S123. Plus poster presented at the 15th International Congress of Parkinson’s Disease and Movement Disorders (MDS); 2011 Jun 5–9; Toronto (ON) Chaudhuri KR, Friedman JH, Surmann E, et al. The effects of transdermal rotigotine on mood/cognition: interpretations from a post-hoc analysis of the RECOVER study using the Parkinson’s Disease Non-Motor Symptom Scale [abstract no. 367]. RECOVER Study Group. Mov Disord 2011 May; 26 Suppl. 2: S123. Plus poster presented at the 15th International Congress of Parkinson’s Disease and Movement Disorders (MDS); 2011 Jun 5–9; Toronto (ON)
39.
Zurück zum Zitat LeWitt PA, Boroojerdi B, Poewe W. Long-term treatment of advanced Parkinson’s disease with rotigotine [abstract no. P04.131]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON) LeWitt PA, Boroojerdi B, Poewe W. Long-term treatment of advanced Parkinson’s disease with rotigotine [abstract no. P04.131]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)
40.
Zurück zum Zitat Ghys L, LeWitt P, Grieger F, et al. Treatment of patients with early and advanced Parkinson’s disease (PD) with transdermal rotigotine: age relationship to safety and tolerability [abstract]. 7th International Congress on Mental Dysfunctions & Other Non-Motor Features in Parkinson’s Disease & Related Disorders; 2010 Dec 9–12; Barcelona Ghys L, LeWitt P, Grieger F, et al. Treatment of patients with early and advanced Parkinson’s disease (PD) with transdermal rotigotine: age relationship to safety and tolerability [abstract]. 7th International Congress on Mental Dysfunctions & Other Non-Motor Features in Parkinson’s Disease & Related Disorders; 2010 Dec 9–12; Barcelona
41.
Zurück zum Zitat UCB. UCB receives complete response letter from US FDA regarding Neupro® (rotigotine) [media release] 2010 April 23 [online]. Available from URL: http://www.ucb.com UCB. UCB receives complete response letter from US FDA regarding Neupro® (rotigotine) [media release] 2010 April 23 [online]. Available from URL: http://​www.​ucb.​com
43.
Zurück zum Zitat Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007 Aug; 64(8): 1083–8PubMedCrossRef Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007 Aug; 64(8): 1083–8PubMedCrossRef
45.
Zurück zum Zitat Aminoff MJ. Treatment should not be initiated too soon in Parkinson’s disease. Ann Neurol 2006 Mar; 59(3): 562–4PubMedCrossRef Aminoff MJ. Treatment should not be initiated too soon in Parkinson’s disease. Ann Neurol 2006 Mar; 59(3): 562–4PubMedCrossRef
46.
Zurück zum Zitat Schapira AHV, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol 2006 Mar; 59: 559–62PubMedCrossRef Schapira AHV, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol 2006 Mar; 59: 559–62PubMedCrossRef
47.
Zurück zum Zitat Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009 May; 8(5): 464–74PubMedCrossRef Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009 May; 8(5): 464–74PubMedCrossRef
48.
Zurück zum Zitat Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of non-motor symptoms of Parkinson’s disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010 Mar 16; 74: 924–31PubMedCrossRef Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of non-motor symptoms of Parkinson’s disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010 Mar 16; 74: 924–31PubMedCrossRef
49.
Zurück zum Zitat Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM. The impact of non-motor symtoms on health-related quality of life of patients with Parkinson’s disease: NMSS Validation Group. Mov Disord 2011 Feb 15; 26(3): 399–406PubMedCrossRef Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM. The impact of non-motor symtoms on health-related quality of life of patients with Parkinson’s disease: NMSS Validation Group. Mov Disord 2011 Feb 15; 26(3): 399–406PubMedCrossRef
50.
Zurück zum Zitat Pfeiffer RE. Gastrointestinal dysfunction in Parkinson’s disease. Clin Neurosci 1998; 5(2): 136–46PubMed Pfeiffer RE. Gastrointestinal dysfunction in Parkinson’s disease. Clin Neurosci 1998; 5(2): 136–46PubMed
51.
Zurück zum Zitat Schnitzler A, Leffers KW, Häck HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2010 Sep; 16(8): 513–6PubMedCrossRef Schnitzler A, Leffers KW, Häck HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2010 Sep; 16(8): 513–6PubMedCrossRef
Metadaten
Titel
Rotigotine Transdermal Patch
A Review of its Use in the Treatment of Parkinson’s Disease
verfasst von
Mark Sanford
Lesley J. Scott
Publikationsdatum
01.08.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 8/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11206750-000000000-00000

Weitere Artikel der Ausgabe 8/2011

CNS Drugs 8/2011 Zur Ausgabe

Adis Drug Evaluation

Fingolimod

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.